APA (7th ed.) Citation

Subbiah, V., Dumbrava, E. I., Jiang, Y., Thein, K. Z., Naing, A., Hong, D. S., . . . Falchook, G. (2020). Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: A phase 1 dose escalation triplet combination trial. Experimental Hematology & Oncology, 9(1), 1. https://doi.org/10.1186/s40164-020-00159-1

Chicago Style (17th ed.) Citation

Subbiah, Vivek, et al. "Dual EGFR Blockade with Cetuximab and Erlotinib Combined with Anti-VEGF Antibody Bevacizumab in Advanced Solid Tumors: A Phase 1 Dose Escalation Triplet Combination Trial." Experimental Hematology & Oncology 9, no. 1 (2020): 1. https://doi.org/10.1186/s40164-020-00159-1.

MLA (9th ed.) Citation

Subbiah, Vivek, et al. "Dual EGFR Blockade with Cetuximab and Erlotinib Combined with Anti-VEGF Antibody Bevacizumab in Advanced Solid Tumors: A Phase 1 Dose Escalation Triplet Combination Trial." Experimental Hematology & Oncology, vol. 9, no. 1, 2020, p. 1, https://doi.org/10.1186/s40164-020-00159-1.